Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Monte Rosa Therapeutics, Inc. GLUE NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
66/100
5/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$31.75
+81.4%

Monte Rosa Therapeutics, Inc. (GLUE) has 12 identified peers for comparison in the Healthcare sector. Peers include DSGN, ERAS, FHTX, GBIO, GRCL, HOWL and others.

GLUE has a market capitalization of $1.14B, compared to an average peer market cap of $1.5B.

People Also View

KYMR
KYMR
Kymera Therapeutics, Inc.
$89.87
+1.51%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 NRIX
NRIX
Nurix Therapeutics, Inc.
$16.30
+2.45%
 SANA
SANA
Sana Biotechnology, Inc.
$3.48
+8.41%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.64
+2.35%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 LYEL
LYEL
Lyell Immunopharma, Inc.
$23.37
-5.77%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message